Analyst
Leerink Partners
Equibles does not estimate personal net worth.
Puneet Suda is recorded as Analyst at Leerink Partners. Puneet Suda has spoken on 16 earnings calls across 9 companies, most recently for Veracyte, Inc. on July 30, 2026. Those appearances were for Natera, Inc. (NTRA), Agilent Technologies, Inc. (A), Repligen Corp (RGEN), Veracyte, Inc. (VCYT), Myriad Genetics Inc (MYGN) and 4 other companies. The companies whose calls Puneet Suda spoke on are classified in the Healthcare sector.
“So just on Decipher, just wondering, you know, Decipher Low Risk, do you believe there was any impact from the ACA disenrollment on the volumes? or was this all largely comp issues that you saw in the quarter?”
“First one on prior authorization, there has been some news lately in terms from CMS and also some of the larger pairs on prior authorization.”
“Just wanted to follow up on the commercial side. Could you update us? You talked about, you know, a number of accounts, you know, sort of 100 account reps versus last year.”
“First one, again, you know, GLP-1 growth there is strong, but my question is more on the utilization on the, you know, the Oligo side, on the NASD side. any update on you know to the full utilization of train c which i think is anticipated in 2027 the question is really around the margin impact in light of this…”
“So first one, I mean, I appreciate the meaningful step up that needs to happen in the fourth fiscal quarter here in organic growth. And I think you gave some underlying drivers to that.”
Leerink Partners
Analyst
Transcript header (unverified)
NTRA
Diagnostics & Research · Healthcare
Diagnostics & Research · Healthcare
RGEN
Medical Instruments & Supplies · Healthcare
VCYT
Diagnostics & Research · Healthcare
MYGN
Diagnostics & Research · Healthcare
TECH
Biotechnology · Healthcare
RVTY
Diagnostics & Research · Healthcare
